96%Confidence
0Views
FDASource
2026-03-15Date
Summary
Wizcure Pharmaa's Vista Meibo Tears recall completes a pattern of multiple sterility failures across their eye care products. This systemic issue likely necessitates regulatory intervention and could lead to import bans or facility shutdowns.
Actionable: Discontinue use of all Vista brand eye products and seek alternative dry eye treatments from manufacturers with robust quality systems.
AI Confidence: 96%
Data Points
firmWizcure Pharmaa Private Limited
classificationClass II
statusOngoing
distributionDistributed Nationwide in the USA
productVista Meibo Tears Propylene Glycol 0.6% w/v Eye Drops Advanced Dry Eye Relief Revitalizing Formula, 10 ml (1/3 fl.oz.), Wizcure Pharmaa PVT. LTD., H-8
Get Signals Instantly
Premium subscribers receive every signal via Telegram the moment it fires — hours before it appears here.
Subscribe Now